Evidence map›Paper›PMID 39290553›Full record

ArticleDermatology reports2024

Preliminary analysis of the melanoma multimedia educational program for general practitioners on behalf of the Italian Melanoma Intergroup.

Federica Zamagni, Fabio Falcini, Serena Magi, Lauro Bucchi, Silvia Mancini, Rosa Vattiato, Emanuele Crocetti, Stefano Falcinelli, Claudio Feliciani, Maurizio Lombardo and 7 more

Abstract read
In one paragraph

Article in Dermatology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Federica ZamagniEmilia-Romagna Cancer Registry, Romagna Cancer Institute, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola.
Fabio FalciniEmilia-Romagna Cancer Registry, Romagna Cancer Institute, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola.
Serena MagiSkin Cancer Unit, IRCCS IRST Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola.
Lauro BucchiEmilia-Romagna Cancer Registry, Romagna Cancer Institute, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola.
Silvia ManciniEmilia-Romagna Cancer Registry, Romagna Cancer Institute, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola.
Rosa VattiatoEmilia-Romagna Cancer Registry, Romagna Cancer Institute, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola.
Emanuele CrocettiEmilia-Romagna Cancer Registry, Romagna Cancer Institute, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola.
Stefano FalcinelliDistrict of Ravenna, AUSL Romagna, Ravenna.
Claudio FelicianiDivision of Dermatology, Department of Medicine and Surgery, University of Parma.
Maurizio LombardoDivision of Dermatology, Department of Medicine and Surgery, Ospedale di Circolo e Fondazione Macchi, ASST dei Sette Laghi, Varese.
Davide MelandriDivision of Dermatology Cesena/Forlì AUSL Romagna and Department of Medicine and Surgery, University of Bologna.
Maria Antonietta PizzichettaDepartment of Dermatology, University of Trieste.
Patrizia ReDistrict of Ravenna, AUSL Romagna, Ravenna.
Francesco RicciIDI-IRCCS, Dermatological Research Hospital, Rome.
Rosanna Rita SattaDepartment of Medicine, Surgery and Pharmacy, University of Sassari.
Sara GandiniDepartment of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Ignazio StanganelliSkin Cancer Unit, IRCCS IRST Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

According to the National Oncological Plan 2023-2027 on the importance of multidisciplinary and interactive e-learning training, the Italian Melanoma Intergroup (IMI) has developed MelaMEd (Melanoma Multimedia Education), a national project for general practitioners (GPs) on the prevention and detection of cutaneous melanoma through an online platform and an online course. MelaMEd enables participants to i) recognize skin lesions that require specialist dermatological assessment, ii) select patients at high risk of melanoma and iii) be informed of the diagnosis and treatment pathway of patients with melanoma. A free online platform and online course were developed and launched in June 2022. Before starting the course, enrolled participants fill out a pre-training questionnaire concerning the basic knowledge of the disease and the recognition and management of suspicious lesions. After the course, participants will fill out the same questionnaire again. The online course will end in December 2023. Here we present a preliminary analysis of the pre-training results (January 2023-July 2023). The data have been analyzed descriptively. So far, five healthcare centers have participated in the project for a total of 1320 participants. Of these, 298 compiled the pre-training questionnaire. Forty-seven percent of them were aged <40 years. Respondents were almost divided between GPs (47%) and resident GPs (48%). Among the theoretical questions, the

Indexed as

diagnosiseducationmelanomamultimediatreatment

Identifiers

PMID39290553
PMCPMC11404542

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.